Nightingale Health
3
EUR
-2.28 %
HEALTH
First North Finland
Medical Equipment & Services
Health Care
4,505 following
-2.28%
-5.66%
-1.64%
-3.85%
+90.48%
+168.82%
+158.62%
-22.24%
-
-41.75%
nightingalehealth.com/investors
Nightingale Health operates in medical technology. The company specializes in the development of medical devices. The product portfolio is broad and includes platforms and services in blood tests that are used for disease prevention purposes. In addition to the main business, service and associated ancillary services are also offered. The business is run globally with the largest presence in Europe.
P/E (adj.) (25e)
-10.78
EV/EBIT (adj.) (25e)
-7.28
P/B (25e)
2.65
Dividend yield-% (25e)
-
Target price
2.90 EUR
Recommendation
Reduce
Updated
23.9.2024
First North Finland
HEALTH
Daily low / high price
2.97 / 3.11
EUR
Market cap
182.76M EUR
Turnover
121.77K EUR
Volume
40K
Business risk
Valuation risk
Current
Previous
Latest research
Extensive report
Inderes' extensive report is an investor's handbook on customer companies covered by our research.
The latest extensive report was released
Read the reportAnalyst
Antti Luiro
Head of Nordic ER Development, Analyst
Latest videos
Financial calendar
Interim report
2025-03-06
Income statement
| 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | 2027e | 2028e | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.3 | 2.3 | 4.2 | 4.4 | 6.5 | 10.8 | 17.3 | 26.8 |
| growth-% | 29.4 % | 0.3 % | 80.8 % | 4.2 % | 50.1 % | 65.1 % | 60.0 % | 55.0 % |
| EBITDA | -7.3 | -9.4 | -12.9 | -10.4 | -9.6 | -8.8 | -6.9 | -3.0 |
| EBIT (adj.) | -8.6 | -13.6 | -18.5 | -18.6 | -17.9 | -15.5 | -12.9 | -8.5 |
| EBIT | -9.8 | -13.6 | -18.5 | -18.6 | -17.9 | -15.5 | -12.9 | -8.5 |
| Profit before taxes | -9.7 | -16.2 | -18.2 | -17.4 | -16.9 | -15.1 | -12.8 | -8.5 |
| Net income | -9.7 | -16.1 | -18.2 | -17.4 | -16.9 | -14.3 | -12.1 | -8.1 |
| EPS (adj.) | -0.21 | -0.23 | -0.30 | -0.29 | -0.28 | -0.23 | -0.20 | -0.13 |
| growth-% | ||||||||
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio |
Profitability and return on capital
| 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | 2027e | 2028e | |
|---|---|---|---|---|---|---|---|---|
| EBITDA-% | -316.7 % | -405.9 % | -308.4 % | -239.4 % | -146.6 % | -81.1 % | -40.1 % | -11.2 % |
| EBIT-% (adj.) | -375.0 % | -589.5 % | -442.9 % | -426.6 % | -273.5 % | -143.2 % | -74.8 % | -31.7 % |
| EBIT-% | -423.2 % | -589.5 % | -442.9 % | -426.6 % | -273.5 % | -143.2 % | -74.8 % | -31.7 % |
| ROE | -15.0 % | -13.7 % | -17.4 % | -19.3 % | -22.3 % | -22.6 % | -22.9 % | -18.2 % |
| ROI | -13.7 % | -11.1 % | -17.1 % | -20.2 % | -23.3 % | -23.9 % | -23.3 % | -17.7 % |
Valuation
| 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | 2027e | 2028e | |
|---|---|---|---|---|---|---|---|---|
| Share price (EUR) | 5.77 | 1.81 | 0.87 | 2.30 | 3.00 | 3.00 | 3.00 | 3.00 |
| Shares | 60.5 | 60.9 | 60.9 | 60.9 | 60.9 | 60.9 | 60.9 | 60.9 |
| Market cap | 349.3 | 110.0 | 53.0 | 140.1 | 182.8 | 182.8 | 182.8 | 182.8 |
| Enterprise value | 241.3 | 19.3 | -25.0 | 74.9 | 130.2 | 143.6 | 154.2 | 165.2 |
| EV/S | 104.7 | 8.3 | - | 17.2 | 19.9 | 13.3 | 8.9 | 6.2 |
| EV/EBITDA | - | - | 1.9 | - | - | - | - | - |
| EV/EBIT (adj.) | - | - | 1.3 | - | - | - | - | - |
| EV/EBIT | - | - | 1.3 | - | - | - | - | - |
| P/E (adj.) | - | - | - | - | - | - | - | - |
| P/E | - | - | - | - | - | - | - | - |
| P/B | 2.8 | 1.0 | 0.5 | 1.7 | 2.7 | 3.2 | 3.8 | 4.5 |
| P/S | 151.5 | 47.6 | 12.7 | 32.2 | 27.9 | 16.9 | 10.6 | 6.8 |
| Dividend yield | ||||||||
| Equity ratio | 88.5 % | 89.8 % | 91.2 % | 91.2 % | 88.3 % | 83.8 % | 76.0 % | 66.6 % |
| Gearing ratio | -87.4 % | -81.3 % | -80.1 % | -78.7 % | -76.2 % | -68.0 % | -58.8 % | -43.4 % |
Quarter data
| Q1/24 | Q2/24 | Q3/24 | Q4/24 | 2024 | Q1/25e | Q2/25e | Q3/25e | Q4/25e | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.7 | 2.6 | 4.4 | 2.9 | 3.6 | ||||
| EBITDA | -5.3 | -5.1 | -10.4 | -5.0 | -4.6 | ||||
| EBIT | -9.3 | -9.3 | -18.6 | -9.2 | -8.7 | ||||
| Profit before taxes | -8.5 | -8.9 | -17.4 | -8.6 | -8.3 | ||||
| Net income | -8.5 | -8.9 | -17.4 | -8.6 | -8.3 |
ShowingAll content types
Nightingale Health Asia achieves ISO 13485:2016 certification and completes regulatory readiness to launch its blood testing service in Singapore
Nightingale Health AGM | CEO's review 8.11.2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Resolutions of the Annual General Meeting and the Board of Directors' organizational meeting of Nightingale Health Plc
Renowned international expert in medicine Dr. Charles Alessi joins Nightingale Health UK as Chief Medical Officer
Nightingale and Boston Heart move from pilot to broader collaboration
Nightingale Health and Boston Heart Diagnostics have successfully completed their pilot and move to the production phase expanding the use of Nightingale's Health Check in the US
Notice to the Annual General Meeting of Nightingale Health Plc
Nightingale Health's Annual Report for financial year 2023-2024 has been published
Conversion of Nightingale Health Plc's Series A shares to Series B shares
Nightingale Health H2'24: World conquest is on a better track
Nightingale, Q4'23
Nightingale Health's Board of Directors resolved on amendment to CEO's incentive program
Nightingale Health Plc Financial Statements Release 1 July 2023 - 30 June 2024
Nightingale Health receives third regulatory approval for healthcare use from Health Sciences Authority in Singapore
